NPI: 1306992136 · NORFOLK, VA 23507 · Pediatrics Physician · NPI assigned 01/26/2007
Authorized official ABSHIRE, KATHRYN controls 20+ related entities in our dataset. Read more
| Authorized Official | ABSHIRE, KATHRYN (SENIOR VP CFO) |
| Parent Organization | CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC |
| NPI Enumeration Date | 01/26/2007 |
Other providers sharing the same authorized official: ABSHIRE, KATHRYN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 24,599 | $898K |
| 2019 | 47,216 | $1.63M |
| 2020 | 47,809 | $1.52M |
| 2021 | 44,668 | $1.32M |
| 2022 | 26,157 | $1.01M |
| 2023 | 28,565 | $1.14M |
| 2024 | 21,266 | $860K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35,792 | 33,787 | $1.99M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17,094 | 16,264 | $1.40M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 16,744 | 16,373 | $1.28M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 18,122 | 15,140 | $1.23M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 12,020 | 11,644 | $887K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5,382 | 5,237 | $436K |
| 90686 | 13,417 | 13,053 | $162K | |
| 92551 | 10,305 | 9,953 | $111K | |
| 90670 | 6,297 | 6,069 | $108K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 9,640 | 5,655 | $89K |
| 90698 | 6,140 | 5,920 | $86K | |
| 96161 | 28,749 | 25,976 | $65K | |
| 96127 | 11,674 | 10,559 | $62K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1,964 | 1,901 | $61K |
| 99205 | Prolong outpt/office vis | 342 | 326 | $52K |
| 99381 | 679 | 598 | $51K | |
| 90651 | 1,600 | 1,564 | $37K | |
| 90680 | 2,506 | 2,403 | $35K | |
| 99188 | 1,379 | 1,352 | $32K | |
| 99215 | Prolong outpt/office vis | 266 | 243 | $31K |
| 90633 | 2,350 | 2,312 | $28K | |
| 96160 | 9,715 | 8,587 | $23K | |
| 90744 | 1,925 | 1,828 | $22K | |
| 99417 | Prolong home eval add 15m | 344 | 309 | $19K |
| 99199 | Unlisted special service, procedure or report | 2,102 | 1,115 | $15K |
| 99173 | 4,398 | 4,219 | $11K | |
| 90734 | 412 | 407 | $8K | |
| 90672 | 541 | 535 | $6K | |
| 99174 | 898 | 889 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 66 | 66 | $5K |
| 90710 | 234 | 231 | $4K | |
| 90696 | 219 | 217 | $3K | |
| S9083 | Global fee urgent care centers | 27 | 27 | $2K |
| 90671 | 74 | 69 | $2K | |
| 90707 | 182 | 178 | $2K | |
| 90619 | 59 | 56 | $2K | |
| 90677 | 37 | 33 | $2K | |
| 1128F | 11,128 | 10,306 | $2K | |
| 90716 | 102 | 101 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 66 | 66 | $2K |
| 0072A | 36 | 32 | $2K | |
| 0001A | 59 | 58 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 89 | 88 | $1K |
| 90715 | 84 | 80 | $1K | |
| 99383 | 12 | 12 | $1K | |
| 94618 | 41 | 40 | $969.09 | |
| 90697 | 31 | 27 | $846.70 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 13 | 12 | $780.57 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 20 | 20 | $600.40 |
| 0002A | 14 | 14 | $592.80 | |
| 91321 | 18 | 15 | $510.00 | |
| 0071A | 12 | 12 | $507.60 | |
| 90620 | 25 | 24 | $459.14 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 15 | 15 | $205.46 |
| 1127F | 2,447 | 2,325 | $75.00 | |
| 99051 | 77 | 75 | $52.90 | |
| 91300 | 180 | 171 | $0.14 | |
| G9920 | Screening performed and negative | 1,230 | 1,135 | $0.00 |
| G9919 | Screening performed and positive and provision of recommendations | 82 | 74 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 40 | 39 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 616 | 547 | $0.00 |
| 91307 | 135 | 122 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 13 | 12 | $0.00 |